HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population

• DOI: 10.1097/qai.0b013e318134257a
• Publication Date: 2007-07-06T08:21:17Z
• Authors: Charlotte Lewden; Geneviève Chêne; Philippe Morlat; François Raffi; Michel Dupon; Pierre Dellamonica; Jean-Luc Pellegrin; Christine Katlama; François Dabis; Catherine Leport
• Keywords: Cart

Objective: To compare mortality rates in combination antiretroviral therapy (cART)-treated HIV-infected adults with the general population according to level of CD4 cell count reached and duration exposure cART. Methods: initiating a protease inhibitor-containing treatment between 1997 1999 were selected Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) APROCO AQUITAINE cohorts. counts estimated during follow-up using 2-phase mixed linear model. Standardized ratios (SMRs) computed reference 2002 French rates, overall for time period spent ≥500 cells/mm3. identify if when values population, SMRs successively truncation at each year follow-up. Results: The 2435 (77% men, baseline median age = 36 years, 270 cells/mm3) had 6.8 years. SMR was 7.0 (95% confidence interval [CI]: 6.2 7.8). During 5402 person-years cells/mm3, after sixth cART initiation (SMR 0.5, 95% CI: 0.1 1.6). Conclusion: Although higher cART-treated adults, subgroup especially good prognosis can be identified, these characteristics should targeted long-term treatment.